截至2026年1月5日收盘，振德医疗(603301)报收于71.56元，上涨1.5%，换手率1.46%，成交量3.87万 手，成交额2.77亿元。 当日关注点 交易信息汇总资金流向 1月5日主力资金净流出1704.33万元，占总成交额6.16%；游资资金净流入1495.06万元，占总成交额 5.4%；散户资金净流入209.27万元，占总成交额0.76%。 公司公告汇总振德医疗2026年第一次临时股东会决议公告 振德医疗于2026年1月5日召开2026年第一次临时股东会，审议通过《关于变更公司住所及修改并办理工 商变更登记的提案》。会议由董事长鲁建国主持，采用现场与网络投票结合方式召开，出席股东所持表 决权占公司总股本的55.8030%。议案为特别决议事项，已获出席会议股东所持表决权的三分之二以上 通过。北京国枫（杭州）律师事务所对本次会议进行了见证并出具法律意见书，认为会议召集、召开程 序及表决结果合法有效。 北京国枫（杭州）律师事务所关于振德医疗用品股份有限公司2026年第一次临时股东会的法律意见书 北京国枫(杭州)律师事务所出具法律意见书，认为振德医疗用品股份有限公司2026年第一次临时股东大 会的召集、 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

证券代码：603301 证券简称：振德医疗 公告编号：2026-001 振德医疗用品股份有限公司 关于第一期员工持股计划存续期 届满暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第一期员工持 股计划（以下简称"本员工持股计划"）延长后的存续期已于 2026 年 1 月 2 日届满。根据中国证监会《关于上市公司实施员工持股计划试 点的指导意见》《上海证券交易所上市公司自律监管指引第 1 号—规 范运作》等相关规定，公司现将相关情况公告如下： 一、本员工持股计划的基本情况 公司分别于 2021 年 5 月 24 日、2021 年 6 月 15 日召开第二届董 事会第十七次会议和 2021 年第二次临时股东大会，审议通过了《关 于<公司第一期员工持股计划（草案）>及其摘要的议案》等相关议案， 同意实施公司第一期员工持股计划，具体内容详见公司于 2021 年 5 月 25 日、2021 年 6 月 16 日在上海证券交易所网站（www.sse.com.cn） 披露的公告。 公 ...

法律意见书 国枫律股字[2026] G0001 号 杭州市上城区新业路8号华联时代大 电话:0571-88362156 传真: 0571-88362156 邮编· 310016 北京国枫(杭州)律师事务所 关于振德医疗用品股份有限公司 2026 年第一次临时股东会的 致:振德医疗用品股份有限公司(贵公司) 北京国枫(杭州)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2026年第一次临时股东会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》(以下简称"《公司章程》"）的规定,就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律意见书。 对本法律意 ...

证券代码：603301 证券简称：振德医疗 公告编号：2026-002 振德医疗用品股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 165 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 148,344,436 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 55.8030 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，以现场投票和网络投票相结合的方式召开，由 董事长鲁建国先生主持会议。本次会议的召集、召开及表决方式符合《公司法》 及《公司章程》的规定。 (二) 关于议案表决的有关情况说明 1、本次股东会以现场投票及网络投票相结合的方式表决通过了以上 1 项议 案。 2、本次股东会所审议议案 1 为特别决议事项，已获出席会议 ...

Group 1 - The article highlights the behavior of margin traders, indicating that investors are looking for investment opportunities through their activities [1] - On December 30, a total of 3,757 stocks received margin buying funds, with the top three stocks being Sanhua Intelligent Controls at 2.296 billion, Zhongji Xuchuang at 2.293 billion, and Xinyi Sheng at 1.910 billion [1] - Among the stocks with significant margin buying, 10 stocks had a margin buying amount that exceeded 30% of their total trading volume [1] Group 2 - The top stocks by margin buying amount and their respective trading volumes and percentages are detailed, with notable mentions including Qingtang City at 24.35 million and Daya Shengxiang at 12.86 million [2] - The data shows that the margin buying percentage for several stocks is high, with Qingtang City at 43.09%, Daya Shengxiang at 40.80%, and Guangming Meat Industry at 35.66% [1][2] - The article provides a comprehensive table listing various stocks, their margin buying amounts, total trading amounts, margin buying percentages, and daily price changes [1][2]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

截至2025年12月26日收盘，振德医疗（603301）报收于72.25元，较上周的67.55元上涨6.96%。本周， 振德医疗12月25日盘中最高价报75.71元。12月22日盘中最低价报66.08元。振德医疗当前最新总市值 192.07亿元，在医疗器械板块市值排名13/127，在两市A股市值排名1020/5178。 本周关注点 公司公告汇总：振德医疗拟将公司住所变更为浙江省绍兴市越城区皋埠街道香积路55号。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总 振德医疗用品股份有限公司拟将公司住所由浙江省绍兴市越城区皋埠街道皋北工业区变更为浙江省绍兴 市越城区皋埠街道香积路55号，并相应修改《公司章程》第五条住所条款。本次变更仅涉及公司住所的 表述调整，邮政编码不变。董事会已审议通过该提案，现提请2026年第一次临时股东会审议，并授权经 营层办理工商变更登记手续。 ...

Core Viewpoint - The stock of Zhendemedical (603301) experienced a decline of 2.51% on December 25, 2025, closing at 71.8 yuan, with significant net inflows from major funds and outflows from retail investors [1][2]. Group 1: Stock Performance and Trading Data - On December 25, 2025, Zhendemedical's trading volume was 58,300 hands, with a total transaction amount of 419 million yuan [1]. - Major funds had a net inflow of 85.32 million yuan, accounting for 20.37% of the total transaction amount, while retail investors had a net outflow of 76.17 million yuan, representing 18.18% of the total [1][2]. - Over the past five days, the stock price fluctuated, with a high of 73.65 yuan on December 24, 2025, and a low of 67.55 yuan on December 19, 2025 [2]. Group 2: Financing and Margin Trading Data - On December 25, 2025, the financing balance was 1.372 billion yuan, with a net financing purchase of 63.66 million yuan [3]. - The margin trading data indicated a total of 1.49 million shares in margin trading, with a margin balance of 1.0698 million yuan [3]. Group 3: Company Financials and Industry Comparison - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, but a net profit of 203 million yuan, a decrease of 33.91% [5]. - The company's gross profit margin stood at 33.93%, significantly lower than the industry average of 51.02%, ranking 97th out of 125 in the industry [5]. - Zhendemedical's total market capitalization is 19.087 billion yuan, with a price-to-earnings ratio of 70.45, which is lower than the industry average of 81.69 [5].

振德医疗用品股份有限公司 2026 年第一次临时股东会会议材料 2026 年 1 月 5 日 振德医疗 2026 年第一次临时股东会材料 振德医疗用品股份有限公司 2026 年第一次临时股东会会议材料目录 第 2页 共 6 页 一、2026 年第一次临时股东会会议议程 二、2026 年第一次临时股东会会议须知 三、《关于变更公司住所及修改<公司章程>并办理工商变更登记的提 案》 振德医疗 2026 年第一次临时股东会材料 振德医疗用品股份有限公司 2026 年第一次临时股东会会议议程 一、现场会议时间及地点 1、时间：2026 年 1 月 5 日（星期一）下午 14 点 00 分。 2、地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医疗用 品股份有限公司会议室。 二、网络投票系统及起止时间 1、网络投票系统：上海证券交易所股东会网络投票系统 2、网络投票起止时间：自 2026 年 1 月 5 日至 2026 年 1 月 5 日。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30， 13:00-15:00；通过互联网 ...